Cabergoline monotherapy in GH- and PRL-cosecreting pituitary adenomas
GH and PRL-PA is a typically aggressive form of pituitary adenoma.Cabergoline monotherapy can be an effective treatment option for select case of GH and PRL-PA, resulting in both biochemical and structural responses.Some GH and PRL-PAs may exhibit a 'hyper-response' to cabergoline with rapid, profound hormone reduction and/or tumour shrinkage.
Authors
- Alistair Jukes (ORCID: https://orcid.org/0000-0002-6363-1366)
- J. S. McNeil
- Sunita M. C. De Sousa
- Nicholas C. Candy
Institutions
- Royal Adelaide Hospital (AU)
- University of South Australia (AU)
- Queen Elizabeth Hospital (AU)
- The University of Adelaide (AU)
Publication Details
- Journal
- Endocrine Oncology
- Published
- 2025-12-18
- DOI
- https://doi.org/10.1530/eo-25-0077
- Primary Topic
- Pituitary Gland Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00